Posted on 02/09/2010 in Marketing Services Quintiles has been appointed by healthcare company Pharmaxis to provide commercial solutions to support the European launch of a new cystic fibrosis drug.
The agreement will see Quintiles take responsibility for creating a market access strategy, establishing a pricing scheme and recruiting commercial teams for the launch of Bronchitol, with promotional activities commencing early next year.
Pharmaxis expects to receive approval for Bronchitol later in 2010 and will release the drug with Quintiles' assistance in Germany in early 2011, with further European launches following afterwards.
Gary Phillips, acting chief executive officer of Pharmaxis, said Quintiles' industry experience makes them the ideal partner to handle the launch of Bronchitol in Europe, which he identified as a "complex area" in which to release a new product.
Mark Archer, vice-president of global business development at Quintiles, added: "We are pleased that Pharmaxis - a leading bio pharma company - has selected Quintiles to provide a tailored solution to commercialise a much-needed therapy."
Last month, Quintiles strengthened its scientific advisory board with the appointment of Dr Aaron Ciechanover, winner of the 2004 Nobel Prize in Chemistry. Other news stories from 02/09/2010
Read more in the Zenopa News Archive
How this news is generated
|
